Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance

Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.

Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.

Spiderwort’s spinal cord scaffold earns scientific validation as its dermal filler enters human trials Spiderwort Biotechnologies Inc. has reported two key developments in its cellulose-based regenerative platform, signaling a step forward in both neurorepair and aesthetic medicine. A peer-reviewed study published in Scientific Reports confirms that the company’s plant-derived scaffolds promote neural tissue repair and […]